洛拉替尼治疗间变性淋巴瘤激酶重排肺癌。
Lorlatinib in ALK-Rearranged Lung Cancer.
机构信息
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
出版信息
Cancer Cell. 2021 Jan 11;39(1):25-27. doi: 10.1016/j.ccell.2020.12.017.
PMID:33434512
Abstract
Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.
摘要
洛拉替尼是否应成为晚期ALK 重排肺癌的标准一线治疗药物？在《新英格兰医学杂志》上，Shaw 等人公布了 CROWN 研究的中期分析结果，该研究是一项随机、III 期研究，比较了洛拉替尼与克唑替尼作为晚期 ALK 重排 NSCLC 患者初始治疗的疗效。
Zotero 插件